Ilaria Muller on a Possible Common Antigen Between Thyroid and Breast Cancers
Muller says if this common antigen does exist, an immune therapy could hypothetically be developed to combat it and essentially combat both breast and thyroid cancer.
Ilaria Muller, PhD student, Cardiff University, on a possible common antigen between thyroid cancer and breast cancer. Muller says if this common antigen does exist, an immune therapy could hypothetically be developed to combat it and essentially combat both breast and thyroid cancer.
Muller sadds that in most forms of thyroid cancer, the thyroid can be removed and replacement treatments for its function can be taken. Muller and colleagues at Cardiff Univeristy are currently investigating the topic of thyroid autoimmunity as a biomarker of outcome in women with breast cancer by way of a large-scale study using data from the Taxotere As Adjuvant Chemotherapy (Tact) Trial (Cruk01/001).
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward
February 20th 2025Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.
Read More
